Journal of Neuroendovascular Therapy
Online ISSN : 2186-2494
Print ISSN : 1882-4072
Original Articles
Preventive Effects of an EPA Preparation on Restenosis after Carotid Artery Stenting
Tomoo OhashiYusuke AraiDaichi KatoShigeru AoyagiHirofumi OkadaTomoya YokoyamaMegumi IchikawaKenta NagaiHiroaki NamatameAkihiko SaidaTakao HashimotoMichihiro Kono
ジャーナル オープンアクセス

2018 年 12 巻 11 号 p. 527-531


Objective: The purpose of this study was to investigate the preventive effects of an eicosapentaenoic acid (EPA) medication on restenosis after carotid artery stenting (CAS).

Methods: Of 134 patients (144 episodes) who underwent CAS in our hospital or affiliated institutions between November 2005 and September 2017, the subjects were 123 who could be followed-up for ≥30 days after procedure by carotid ultrasonography with a mean age of 73.3 years (range: 55–90 years). Males accounted for 106 (86.2%) of the patients, 61 lesions (49.6%) were symptomatic. We retrospectively compared the incidence of restenosis between the two groups: EPA-treated group (n = 43) and non-EPA-treated group (n = 80). In addition, the serum levels of fatty acid compositions had been analyzed in 97 of the 123 patients, and the relationship of the EPA/arachidonic acid (AA) ratio with perioperative ischemic complications or restenosis was examined.

Results: There was no restenosis in any of the 43 EPA-treated patients, whereas it occurred in 8 (10%) of the 80 patients in the non-EPA-treated group, and the incidence of restenosis in EPA-treated group was significantly lower (p = 0.043) than that of non-EPA-treated group. In addition, the incidences of restenosis and perioperative ischemic complications were slightly higher in patients with a low EPA/AA ratio.

Conclusion: Although restenosis was more frequent in patients with a low EPA/AA ratio, the administration of an EPA medication may prevent restenosis in all patients who underwent CAS.